vs

Side-by-side financial comparison of Professional Diversity Network, Inc. (IPDN) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

TScan Therapeutics, Inc. is the larger business by last-quarter revenue ($2.6M vs $1.7M, roughly 1.5× Professional Diversity Network, Inc.). Professional Diversity Network, Inc. runs the higher net margin — -173.5% vs -895.1%, a 721.6% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs 3.1%). Professional Diversity Network, Inc. produced more free cash flow last quarter ($1.4M vs $-32.2M). Over the past eight quarters, Professional Diversity Network, Inc.'s revenue compounded faster (-1.7% CAGR vs -9.7%).

Professional Diversity Network, Inc. is a U.S.-based firm offering end-to-end diversity, equity and inclusion (DEI) solutions for corporate clients. Its services include targeted recruitment support for underrepresented talent groups, customized DEI training programs, and diversity performance data analytics, serving clients across tech, healthcare, finance and other core commercial sectors nationwide.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

IPDN vs TCRX — Head-to-Head

Bigger by revenue
TCRX
TCRX
1.5× larger
TCRX
$2.6M
$1.7M
IPDN
Growing faster (revenue YoY)
TCRX
TCRX
+282.9% gap
TCRX
286.0%
3.1%
IPDN
Higher net margin
IPDN
IPDN
721.6% more per $
IPDN
-173.5%
-895.1%
TCRX
More free cash flow
IPDN
IPDN
$33.6M more FCF
IPDN
$1.4M
$-32.2M
TCRX
Faster 2-yr revenue CAGR
IPDN
IPDN
Annualised
IPDN
-1.7%
-9.7%
TCRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IPDN
IPDN
TCRX
TCRX
Revenue
$1.7M
$2.6M
Net Profit
$-2.9M
$-23.0M
Gross Margin
33.7%
Operating Margin
-173.2%
-929.4%
Net Margin
-173.5%
-895.1%
Revenue YoY
3.1%
286.0%
Net Profit YoY
-280.0%
35.8%
EPS (diluted)
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IPDN
IPDN
TCRX
TCRX
Q4 25
$1.7M
$2.6M
Q3 25
$1.7M
$2.5M
Q2 25
$1.6M
$3.1M
Q1 25
$1.5M
$2.2M
Q4 24
$1.6M
Q3 24
$1.7M
$1.0M
Q2 24
$1.7M
Q1 24
$1.7M
Net Profit
IPDN
IPDN
TCRX
TCRX
Q4 25
$-2.9M
$-23.0M
Q3 25
$-2.4M
$-35.7M
Q2 25
$-476.0K
$-37.0M
Q1 25
$-722.1K
$-34.1M
Q4 24
$-761.9K
Q3 24
$-405.0K
$-29.9M
Q2 24
$-553.1K
Q1 24
$-791.8K
Gross Margin
IPDN
IPDN
TCRX
TCRX
Q4 25
33.7%
Q3 25
44.0%
Q2 25
43.4%
Q1 25
52.2%
Q4 24
58.6%
Q3 24
58.9%
Q2 24
62.9%
Q1 24
62.2%
Operating Margin
IPDN
IPDN
TCRX
TCRX
Q4 25
-173.2%
-929.4%
Q3 25
-136.3%
-1475.6%
Q2 25
-30.2%
-1256.6%
Q1 25
-46.9%
-1669.7%
Q4 24
-36.8%
Q3 24
-25.0%
-3109.8%
Q2 24
-34.4%
Q1 24
-46.5%
Net Margin
IPDN
IPDN
TCRX
TCRX
Q4 25
-173.5%
-895.1%
Q3 25
-136.2%
-1422.1%
Q2 25
-29.0%
-1201.3%
Q1 25
-48.0%
-1571.9%
Q4 24
-47.1%
Q3 24
-23.9%
-2849.1%
Q2 24
-32.7%
Q1 24
-45.9%
EPS (diluted)
IPDN
IPDN
TCRX
TCRX
Q4 25
$-0.18
Q3 25
$-0.28
Q2 25
$-0.28
Q1 25
$-0.26
Q4 24
Q3 24
$-0.25
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IPDN
IPDN
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$217.0K
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$11.7M
$123.1M
Total Assets
$17.9M
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IPDN
IPDN
TCRX
TCRX
Q4 25
$217.0K
$152.4M
Q3 25
$265.3K
$184.5M
Q2 25
$125.1K
$218.0M
Q1 25
$496.4K
$251.7M
Q4 24
$1.7M
Q3 24
$133.7K
$271.1M
Q2 24
$619.3K
Q1 24
$97.1K
Total Debt
IPDN
IPDN
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
IPDN
IPDN
TCRX
TCRX
Q4 25
$11.7M
$123.1M
Q3 25
$8.9M
$144.0M
Q2 25
$4.5M
$176.7M
Q1 25
$4.9M
$210.2M
Q4 24
$5.3M
Q3 24
$2.1M
$229.1M
Q2 24
$2.5M
Q1 24
$2.3M
Total Assets
IPDN
IPDN
TCRX
TCRX
Q4 25
$17.9M
$228.8M
Q3 25
$12.1M
$262.2M
Q2 25
$7.3M
$298.6M
Q1 25
$7.7M
$332.7M
Q4 24
$8.0M
Q3 24
$5.3M
$348.0M
Q2 24
$5.8M
Q1 24
$5.7M
Debt / Equity
IPDN
IPDN
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IPDN
IPDN
TCRX
TCRX
Operating Cash FlowLast quarter
$1.4M
$-32.0M
Free Cash FlowOCF − Capex
$1.4M
$-32.2M
FCF MarginFCF / Revenue
84.4%
-1253.3%
Capex IntensityCapex / Revenue
0.0%
6.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IPDN
IPDN
TCRX
TCRX
Q4 25
$1.4M
$-32.0M
Q3 25
$-2.7M
$-32.5M
Q2 25
$-495.5K
$-33.3M
Q1 25
$-284.1K
$-37.6M
Q4 24
$-1.2M
Q3 24
$-556.9K
$-27.9M
Q2 24
$-224.4K
Q1 24
$-543.1K
Free Cash Flow
IPDN
IPDN
TCRX
TCRX
Q4 25
$1.4M
$-32.2M
Q3 25
$-2.7M
$-33.9M
Q2 25
$-499.5K
$-34.5M
Q1 25
$-39.1M
Q4 24
$-1.2M
Q3 24
$-558.9K
$-29.3M
Q2 24
$-225.9K
Q1 24
$-543.6K
FCF Margin
IPDN
IPDN
TCRX
TCRX
Q4 25
84.4%
-1253.3%
Q3 25
-156.8%
-1349.6%
Q2 25
-30.4%
-1123.1%
Q1 25
-1801.8%
Q4 24
-74.0%
Q3 24
-33.0%
-2792.0%
Q2 24
-13.4%
Q1 24
-31.5%
Capex Intensity
IPDN
IPDN
TCRX
TCRX
Q4 25
0.0%
6.7%
Q3 25
0.0%
56.8%
Q2 25
0.2%
41.6%
Q1 25
0.0%
70.6%
Q4 24
1.3%
Q3 24
0.1%
130.6%
Q2 24
0.1%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons